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Self-reported memory complaints
Implications from a longitudinal cohort with autopsies
ABSTRACT
Objective: We assessed salience of subjective memory complaints (SMCs) by older individuals as
a predictor of subsequent cognitive impairment while accounting for risk factors and eventual
neuropathologies.
Methods: Subjects (n 5 531) enrolled while cognitively intact at the University of Kentucky were
asked annually if they perceived changes in memory since their last visit. A multistate model
estimated when transition to impairment occurred while adjusting for intervening death. Risk
factors affecting the timing and probability of an impairment were identified. The association
between SMCs and Alzheimer-type neuropathology was assessed from autopsies (n 5 243).
Results: SMCs were reported by more than half (55.7%) of the cohort, and were associated with
increased risk of impairment (unadjusted odds ratio 5 2.8, p , 0.0001). Mild cognitive impair-
ment (dementia) occurred 9.2 (12.1) years after SMC. Multistate modeling showed that SMC
reporters with an APOE e4 allele had double the odds of impairment (adjusted odds ratio 5 2.2,
p 5 0.036). SMC smokers took less time to transition to mild cognitive impairment, while SMC
hormone-replaced women took longer to transition directly to dementia. Among participants (n 5
176) who died without a diagnosed clinical impairment, SMCs were associated with elevated
neuritic amyloid plaques in the neocortex and medial temporal lobe.
Conclusion: SMC reporters are at a higher risk of future cognitive impairment and have higher lev-
els of Alzheimer-type brain pathology even when impairment does not occur. As potential har-
bingers of future cognitive decline, physicians should query and monitor SMCs from their older
patients. Neurology® 2014;83:1359–1365
GLOSSARY
AD5 Alzheimer disease; BRAiNS5 Biologically Resilient Adults in Neurological Studies; CERAD5 Consortium to Establish
a Registry for Alzheimer’s Disease; HRT 5 hormone replacement therapy; MCI 5 mild cognitive impairment; MTL 5 medial
temporal lobe; NFT 5 neurofibrillary tangle; NP 5 neuritic plaque; NSI 5 no serious impairment; OR 5 odds ratio; SMC 5
subjective memory complaint.
Subjective memory complaints (SMCs) may signal increased risk of progression into clinically
recognized states of impairment, namely, mild cognitive impairment (MCI) and dementia.1–5
Although prior studies use incident dementia as an endpoint, there is a need to consider the
effect of SMC on the occurrence of MCI as well.6 Little is known about risk factors associated
with the occurrence of SMCs other than depression or poor psychological well-being.7 SMCs
may reflect aspects of metamemory, as older adults monitor their own forgetting.8 Persons with
SMC may show MRI-based hippocampal atrophy, a finding also seen in MCI.9 Finally, while
Alzheimer disease (AD)-type neuropathologic changes occur years before clinical symptoms are
detectable, only a few studies link SMC to neuropathology10,11 or to biomarkers.2
We hypothesized that baseline cognitively intact subjects who declared an SMC would be at a
higher risk of a cognitive impairment and may harbor AD-type brain pathology even in the
absence of observable impairment. We analyzed data from a longitudinal cohort study
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(Biologically Resilient Adults in Neurological
Studies [BRAiNS]).12,13 We assessed risk fac-
tors associated with incident SMCs, MCI,
dementia, or death without dementia, as well
as the time to each endpoint using data from
531 volunteers. Because approximately half of
this cohort has come to autopsy, we also inves-
tigated the relationship between each endpoint
and AD-type brain pathology.
METHODS Subjects. BRAiNS is a cohort of more than 1,100
older individuals aged at least 60 years enrolled in a longitudinal
study of aging and cognition at the University of Kentucky’s
Alzheimer’s Disease Center.12 Participants agree to postmortem
brain donation. Enrollment criteria exclude persons younger than
60 years, and those with active infectious diseases, neurologic
disorders, dementing illness, psychiatric disorders including
depression, or disabling medical disorders.12 Subjects included
in the current analysis (n 5 531) had at least 2 study visits,
had APOE genotyping available, and enrolled before the initia-
tion of the National Alzheimer’s Coordinating Center Uniform
Data Set in 2005. These participants have been the subject of
previous reports.14 All subjects were cognitively intact at entry.
Standard protocol approvals, registrations, and patient
consents. The University of Kentucky institutional review board
approved all research activities, and each participant gave written
informed consent.
Cognitive assessments. The authors classified participants into
4 mutually exclusive cognitive states based on the results of the
annual assessments, which included multiple measures of mem-
ory, language, executive, and visuospatial function12: no serious
impairment (NSI), SMC, clinical MCI, or dementia. Before
administration of the neurocognitive battery, participants were
systematically asked if they had noticed any change in memory
since their last visit. Participants entered the SMC state based on
the date of their first “yes” response, provided no clinical impair-
ment had yet been diagnosed. The diagnosis of clinical MCI or
dementia was by a consensus team review; for detailed diagnostic
criteria, see Abner et al.15
Cognitive states. The NSI state encompasses participants who
did not die or transition into SMC, MCI, or dementia between
assessments (figure 1). Hence, persons in the NSI state may
perform below expectation on some cognitive assessments but
fail to qualify for a more severe diagnosis.15 Transitions from
more impaired to less impaired states are prohibited in the model.
Although 19 subjects made an apparent recovery from clinical
MCI to NSI at individual assessments, a review determined these
to be artifacts resulting from either underlying comorbidities or
diagnostic misclassification; we recoded these diagnoses accord-
ingly so that all transitions flow consistently from less impaired to
more impaired.12
Risk factors. A literature review identified potential risk factors
for transitions among the clinical states (figure 1): APOE e4 car-
rier status (e4 allele positive/negative), female sex, low education
(high school or less), overweight (body mass index .25 kg/m2),
family history of dementia among first-degree relatives, smoking
(never, former, or current smoker), high blood pressure, use of
estrogen hormone replacement therapy (HRT), and presence of
type II diabetes. Self-reports determine the latter 4 variables. Age
is the time scale in the semi-Markov model and not a risk factor
otherwise.
While procedures currently include annual neurocognitive,
physical, and neurologic examinations, during the first 6 years
of the study, only neurocognitive measures were collected annu-
ally, and medical history was collected during the baseline inter-
view only. Accordingly, all risk factor exposures were fixed at
baseline and coded as indicator variables.
Neuropathologic analysis. The autopsy rate for participants
who died during follow-up is 84.7%. University of Kentucky’s
Alzheimer’s Disease Center neuropathologists performed autopsy
assessments including lesion counts using previously described
methods.16,17 Briefly, brain regions sampled include middle frontal
gyrus (Brodmann area 9), superior and middle temporal gyri (areas
21 and 22), inferior parietal lobule (areas 39 and 40), occipital lobe
including primary visual area (areas 17 and 18), amygdala, entorhinal
cortex, and hippocampal CA1 and subiculum. Then mean neuritic
plaques (NPs) (number/2.35 mm2) and neurofibrillary tangles
(NFTs) (number/0.586 mm2) were generated per brain region
based on the 5 most involved fields (subjectively determined). We
averaged counts into 2 brain regions for data analysis: the medial
temporal lobe (MTL) and neocortex. In addition, Consortium to
Establish a Registry for Alzheimer’s Disease (CERAD) ratings were
derived from NP counts.18
Statistical analysis. A semi-Markov model describes the
movement of participants through the 5 clinical states (figure 1).
Participants contribute up to 3 transitions to the analysis. Each
transition involves 2 quantities: the probability of making that
transition and, independently, the time required for that
transition to occur (i.e., age of the first transition from NSI to
another state or the time spent in SMC/MCI). Assuming a
polytomous logistic model determines the probability of a
transition, the analysis generated estimates of odds ratios (ORs)
associated with risk factors affecting these probabilities; the
logistic model depends on the participant’s current state: NSI,
SMC, or MCI. In all cases, the OR compares the odds of a
transition to the state of interest vs the odds of a transition to
death. Assuming each holding time follows a Weibull distribution
that depends on both the current state and the state being
entered, the analysis determines how the risk factors affect the
mean holding time. Kryscio et al.14 describe the strategy for
identifying significant risk factors associated with these
probabilities and holding times. In this application, we assumed
the transition to SMC occurred on the date the participant first
admitted to an SMC, but the transitions to MCI and/or dementia
were interval censored. Generalizing the equations discussed in
Figure 1 Flow diagram and frequency of transitions among states
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Foucher et al.19 for a 4-state model to account for the SMC state,
we fit the model to the data using PROC NLIN in PC-SAS/
STAT 9.3 (equations and program available upon request).
We assessed NP and NFT count distributions in the 4
groups: (1) both SMC and impaired negative, (2) SMC positive
but impaired negative, (3) SMC negative but impaired positive,
and (4) both SMC and impaired positive. Here, impaired refers
to a diagnosis of MCI or dementia. We used Wilcoxon rank
sum tests to compare groups 1 to 2, 1 to 3, 2 to 4, and 3 to 4
in each brain region.
RESULTS The participant group was relatively young
at enrollment, majority female, had relatively high edu-
cational attainment, high risk of dementia (evidenced
by high proportion of APOE e4 carriers and family
history of dementia), and a high proportion of current
or former cigarette smokers (see table 1). The mean
number of annual assessments per participant was
10.3 6 4.1.
Probability of a transition. Approximately 25% of the
living participants remained in the NSI state at the last
observed assessment. Of decedents, 11.7% were in the
NSI state at last assessment, and another 23.9% had
transitioned to the SMC state (figure 1). Almost 1 in
5 subjects (19.7%) met the clinical criteria for MCI
during follow-up, and 68.6% of these entered the
SMC state before this diagnosis. Approximately 1 in
6 subjects (16.6%) became demented during follow-
up, and 79.6% of these first entered the SMC state. In
total, the majority of the cohort entered the SMC state
(296/531 or 55.7%). Those entering the SMC state
had increased odds of subsequent impairment (either
MCI or dementia) vs dying when compared with all
others (OR5 2.8; 95% confidence interval: 1.9–4.2).
The presence of type II diabetes and current smok-
ing decreased the odds of transition into the SMC
state (table 2). This apparently counterintuitive result
is because these risk factors promote mortality (a com-
peting risk for cognitive impairment), thus decreasing
the at-risk period for SMCs to occur. Current smok-
ing and female sex reduced the risk of transition from
NSI directly into MCI, while high blood pressure
promoted this transition (OR 5 8.4) (table 2). Once
in the SMC state, an APOE e4 carrier had increased
odds of moving into MCI or dementia (OR 5 2.2)
when compared with a transition to death. Also, while
in SMC, high blood pressure (OR 5 3.0) and female
sex (OR 5 2.6) promoted transition directly into
dementia vs death.
Mean time for a transition.Mean holding times in each
state, and risk factors affecting these means, varied lit-
tle by destination state (table 3). For example, sub-
jects entered the states of MCI, dementia, and death
at an average age of 82.6, 84.2, and 90.0 years, respec-
tively, meaning it took 9.4, 11.0, and 16.8 years for
these events to occur from enrollment. The time to
death, which again is a competing risk, was shortened
by almost 5 years for former smokers and almost 9
years for current smokers. Of particular interest was
the mean age for a transition from NSI into SMC
(81.5 years), which implies that on average 8.3 years
were required for participants to declare that they
noticed a memory change since the last visit. This
mean was abbreviated to 79.1 years for overweight
subjects and to 79.6 years for subjects with a family
history of dementia.
The transition from SMC to MCI took 9.2 years
on average (this interval is abbreviated by 2.8 years
for former smokers), and another 2.9 years on aver-
age was required to observe a conversion from MCI
Table 1 Baseline characteristics of the cohort
(n 5 531)
Baseline characteristic Summary
Age, y 73.2 6 7.4
Years of education 16.0 6 2.4
Low education (<13 y) 11.7
Female 63.1
APOE e4 carrier 30.3
Family history of dementia 40.3
Ever smoker 52.7
Former smoker 43.5
Baseline smoker 9.2
Type II diabetes 8.3
Body mass index >25 kg/m2 42.7
High blood pressure 36.5
Hormone replacement therapy (% all
subjects)
18.6
Results presented are mean 6 SD or percent.
Table 2 ORs for transition to a state vs dying for significant baseline risk
factors
From To Baseline risk factor OR (95% CI)
NSI MCI Current smoker 0.21 (0.05–0.98)
Female 0.29 (0.15–0.57)
High blood pressure 8.4 (2.2–32.2)
NSI SMC Diabetes 0.35 (0.17–0.72)
Current smoker 0.25 (0.12–0.52)
MCI Dementia High blood pressure 0.28 (0.09–0.86)
Family history of dementia 3.3 (1.9–10.0)
SMC MCI APOE e4 carrier 2.2 (1.2–4.1)
SMC Dementia APOE e4 carrier 2.2 (1.1–4.6)
High blood pressure 3.0 (1.2–7.5)
Female 2.6 (1.1–5.8)
Abbreviations: CI 5 confidence interval; MCI 5 mild cognitive impairment; NSI 5 no serious
impairment; OR 5 odds ratio; SMC 5 subjective memory complaint.
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to dementia. Having at least one APOE e4 allele
doubles (OR 5 2.2) the odds of a transition from
SMC to either impairment vs dying. A small per-
centage (14.2%) of participants converted from
SMC directly to dementia in 6.1 years on average;
women and hypertensive individuals were most at
risk for this latter transition. For HRT users, the
transition from SMC directly to dementia was
lengthened by 9.7 years. Finally, we note that the
127 of 296 subjects (42.9%) who entered SMC but
died without a clinical impairment spent 9.9 years
on average in SMC. This interval was shortened for
APOE e4 carriers and former smokers to near 6
years.
Neuropathology. Almost half of the cohort has come to
autopsy (243/531 or 45.7%); most others remain active
in the cohort (244/288). To conduct our analysis, we
classified the deceased participants with and without
SMC by their impairment status (MCI or dementia),
yielding 4 comparison groups: SMC negative and
impaired negative (n5 56), SMC positive but impaired
negative (n 5 120), SMC negative but impaired posi-
tive (n5 17), and SMC positive and impaired positive
(n 5 50). The analyses focused on AD-type brain
pathology.20 Boxplots of the NP and NFT counts for
each group in theMTL and neocortex appear in figure 2.
Among unimpaired participants, mean NP
counts in the MTL and neocortex were significantly
higher for SMC positive compared with SMC nega-
tive (p , 0.03 in both regions; Wilcoxon test).
However, among SMC positives, mean NP and
NFT counts were still significantly lower in the
unimpaired participants (p , 0.001 in both re-
gions). In contrast, mean NFT counts in the unim-
paired SMC-positive vs SMC-negative group were
not different (p 5 0.13 [MTL] and p 5 0.27 [neo-
cortex]). The percentage of autopsies blindly rated at
level 3 or 4 (CERAD NP severity moderate or
severe)18 increased monotonically: 23.2%, 36.7%,
58.8%, and 76.0% for the groups SMC and
impaired negative, SMC positive but impaired neg-
ative, SMC negative but impaired positive, and
SMC and impaired positive, respectively.
DISCUSSION This study constitutes a thorough
examination of the appearance of, and salient events fol-
lowing, self-declared memory complaints in a cohort of
well-characterized older adults who volunteered for
Table 3 Mean age at first transition from the NSI state and mean holding time in the SMC and MCI states
From To Baseline risk factor Mean age, y (95% CI)
NSI MCI — 82.6 (79.9–85.2)
Dementia — 84.2 (77.9–90.5)
Death — 90.0 (86.4–93.7)
Former smoker 85.2 (77.5–92.9)
Current smoker 81.3 (67.4–95.2)
SMC — 81.5 (80.2–82.8)
BMI .25 kg/m2 79.1 (72.6–85.5)
Family historya 79.6 (73.4–85.8)
From To Baseline risk factor Mean holding time, y (95% CI)
MCI Dementia — 2.9 (2.4–3.4)
Current smoker 0.7 (0.0–1.5)
HRT 1.3 (0.8–1.9)
Death — 6.0 (4.2–7.8)
SMC MCI — 9.2 (7.3–11.2)
Former smoker 6.4 (5.0–7.8)
Dementia — 6.1 (4.5–7.7)
HRT 15.8 (7.4–24.2)
Death — 9.9 (7.4–12.4)
APOE e4 carrier 5.9 (4.0–7.9)
Former smoker 6.0 (4.6–7.4)
Current smoker 5.3 (3.2–7.3)
Abbreviations: BMI 5 body mass index; CI 5 confidence interval; HRT 5 hormone replacement therapy; MCI 5 mild cog-
nitive impairment; NSI 5 no serious impairment; SMC 5 subjective memory complaint.
a Family history of dementia.
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annual cognitive assessments and brain donation upon
death. The majority of the subjects enrolled in the
BRAiNS cohort (55.7%) declared SMCs, which is
supported by results from the Nurses’ Health Study,
in which 56.4% of the participants declared a recent
change in their ability to remember things.21
We found that SMC represented a higher risk of a
subsequent criterion-based diagnosis of cognitive
impairment, either clinical MCI or dementia, in agree-
ment with much of the previous literature,1,4,6,22
although some studies did not observe SMC as a prog-
nostic factor.5,23 Little has been reported, however,
about the time required for such transitions to occur.
The current study noted these changes occurred at age
81.5 years on average, approximately 8.3 years after
enrollment into the cohort. Furthermore, the interval
between the initial SMC and diagnosis of impairment
was lengthened or shortened by multiple risk factors,
which suggests that SMCs may signal an opportunity
for intervention before clinical impairment manifests.
Recent research correlates the presence of SMC
and biomarkers including brain region volumes,24–26
amyloid burden,26 brain atrophy,9 and gray matter
atrophy,27 and is consistent with earlier neuropatho-
logic reports.13,28 In this study, neuropathology was
obtained on a large proportion of participants who
died. It is important to note that while 42.9% of
SMC subjects died with no observable clinical impair-
ment, one-third of these had AD pathology by
CERAD criteria at autopsy. The SMC-positive but
unimpaired group had elevated NP counts in both
the neocortex and MTL when compared with the 50
subjects in the cohort who died without SMC or
clinical impairment.
While SMC has been shown to correlate with AD-
type pathology regardless of impairment,11 the current
study showed a strong impairment effect. Specifically,
in the absence of clinical impairment, SMC-positive
individuals had elevated NP counts when compared
with SMC-negative individuals, but these counts were
still significantly less when compared with SMC-
positive and impaired participants, which is consistent
with current concepts of preclinical AD.29 Also consis-
tent with earlier reports, the NFT counts did reveal an
SMC effect because these counts were not elevated
unless the participant was impaired.17
The elevated neuritic amyloid plaque counts
appear to be driven partially by the presence of an
APOE e4 allele. APOE e4 carriers had significantly
higher NP counts in the neocortex compared with
noncarriers (p 5 0.003; Wilcoxon rank sum test).
Because participants were blinded to their APOE sta-
tus, these results suggest an interaction between the
APOE e4 genotype and SMC, such that carriers with
SMC were more likely to show AD-type changes.
This interaction hypothesis is supported by a recent
study that shows that smaller hippocampal volumes
are associated with SMC positives among carriers but
larger volumes are associated with SMC positives
among noncarriers.30 However, an SMC-positive
APOE e4 carrier had an abbreviated time to death
without any cognitive impairment (mean time
reduced from 9.9 to 5.9 years).
This study has some limitations. SMC assessment
was measured by one simple question each year on
memory changes since the last visit. No informant
was involved, and no further probing of the participant
with an SMC was conducted. This could partially
explain why approximately one-third of the SMC sub-
jects died without ever converting to a cognitive impair-
ment, although we provide evidence that this subset of
Figure 2 Boxplots of neuritic plaque counts and neurofibrillary tangle counts in
2 brain regions
The boxplots provide neuritic plaque (NP) (A) and neurofibrillary tangle (NFT) (B) counts for each
of 4 groups (in order and shaded light to dark): subjective memory complaint (SMC) negative
and impaired negative; SMC positive and impaired negative; SMC negative and impaired pos-
itive; and SMC positive and impaired positive. *p , 0.05, ***p , 0.001.
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individuals was more likely to harbor NPs. Moreover,
once an SMC is reported in the cohort, 70% of subse-
quent queries confirm the SMC. In addition, all partic-
ipants were self-selected volunteers; APOE e4 carriers
and individuals with positive family history are overrep-
resented because of their concerns about their own risk
of AD. Thus, selection bias could affect the results.
Furthermore, SMCs are often associated with depressive
symptoms,7,31,32 but objective ratings of depression were
not available for this cohort. However, clinical depres-
sion is an exclusionary criterion for entry into the
BRAiNS cohort. Hence, while participants may have
developed depressive symptoms during follow-up, it is
unlikely that clinical depression had a major role in this
study. Finally, several risk factors, including smoking,
body mass index, HRT, diabetes, and high blood pres-
sure were recorded only at baseline and could have
changed during the study. Moreover, because these fac-
tors were derived from self-reports, some cases may have
been misclassified. These limitations are to be weighed
against the substantial follow-up and high autopsy rate
on these well-characterized study participants.
The present study adds strong evidence to the lit-
erature supporting the hypothesis that SMCs are
common among older adults and are often prognos-
tic of future cognitive impairment. Physicians
should solicit and monitor SMCs from their older
patients. However, as shown here, SMCs are not a
cause for immediate alarm because impairments
could be many years away or preempted by death.
Also, older adults with subjective complaints do har-
bor increased NPs regardless of impairment, a find-
ing that has implications for the design of dementia
prevention studies.
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